Maurice Hilleman | Academic Influence

Why Is Maurice Hilleman Influential?

According to Wikipedia, Maurice Ralph Hilleman was a leading American microbiologist who specialized in vaccinology and developed over 40 vaccines, an unparalleled record of productivity. According to one estimate, his vaccines save nearly eight million lives each year. Many have described him as one of the most influential vaccinologists of all time.

Maurice Hilleman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Human hepatitis B vaccine from recombinant yeast (1984) (672)
Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. (1967) (648)
The Vacuolating Virus, S.V.40 (1960) (453)
Live attenuated varicella virus vaccine. Efficacy trial in healthy children. (1984) (410)
Propagation of Human Hepatitis A Virus in Cell Culture in Vitro (1979) (375)
Protective efficacy of pneumococcal polysaccharide vaccines. (1977) (326)
Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. (2002) (320)
Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. (1967) (260)
Vaccination and Revaccination with Polyvalent Pneumococcal Polysaccharide Vaccines in Adults and Infants (1978) (235)
Development of Tumors in Hamsters Inoculated in the Neonatal Period with Vacuolating Virus, SV40 ∗ (1962) (203)
Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. (2000) (189)
Adenoviruses: group name proposed for new respiratory-tract viruses. (1956) (187)
Live, attenuated mumps-virus vaccine. (1968) (178)
Purification and Characterization of Chick Embryo Interferon (1963) (169)
Specific Immune Adherence Assay for Human Hepatitis A Antibody. Application to Diagnostic and Epidemiologic Investigations (1975) (166)
Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections (2004) (159)
Live Attenuated Mumps Virus Vaccine. 1. Vaccine Development (1966) (147)
Antigenic variation of influenza viruses. (1954) (144)
Contributions to Characterization and Classification of Animal Viruses (1963) (133)
Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA). (1967) (130)
Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. (1981) (125)
Development and evaluation of the Moraten measles virus vaccine. (1968) (118)
Purified and inactivated human hepatitis B vaccine: progress report. (1975) (117)
Characterization and Classification of ECHO 28-Rhinovirus-Coryzavirus Agents (1962) (115)
Inducers of interferon and host resistance, V. In vitro studies. (1968) (114)
Physical, Chemical and Morphologic Dimensions of Human Hepatitis A Virus Strain CR326 (1975) (111)
Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage. (1967) (111)
Evidence for viral hepatitis other than type A or type B among persons in Costa Rica. (1975) (108)
Vaccine against human hepatitis B. (1976) (101)
A Specific Complement-Fixation Test for Human Hepatitis A Employing CR326 Virus Antigen. Diagnosis and Epidemiology (1975) (99)
Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. (1967) (99)
Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. (2001) (98)
Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. (2003) (94)
New Findings in Live, Attenuated Hepatitis A Vaccine Development (1986) (93)
Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. (2001) (88)
Acute respiratory illnesses among children and adults. Field study of contemporary importance of several viruses and appraisal of the literature. (1962) (88)
Pneumococcal Vaccines (1978) (86)
Etiologic Relationship of Marmoset-Propagated CR326 Hepatitis A Virus to Hepatitis in Man (1973) (85)
An Inactivated Hepatitis A Virus Vaccine Prepared from Infected Marmoset Liver (1978) (80)
Studies in Human Subjects of Polyvalent Pneumococcal Vaccines (1977) (78)
Live attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. (1967) (77)
Overview: cause and prevention in biowarfare and bioterrorism. (2002) (76)
Combined live measles, mumps, and rubella virus vaccines. (1969) (75)
Tests in Hamsters for Oncogenic Quality of Ordinary Viruses Including Adenovirus Type 7.∗ (1964) (74)
Interruption of SV40 Virus Tumorigenesis Using Irradiated Homologous Tumor Antigen.∗ (1964) (72)
Inducers of Interferon and Host Resistance VI. Antiviral Efficacy of Poly I:C in Animal Models (1969) (70)
Progress toward a Live, Attenuated Human Hepatitis A Vaccine (1982) (66)
Prospects for the use of double-stranded ribonucleic acid (poly I:C) inducers in man. (1970) (62)
Recovery of New Viruses (Coryzavirus) from Cases of Common Cold in Human Adults (1961) (60)
Recovery of Hepatitis Agents in the Marmoset from Human Cases Occurring in Costa Rica (1973) (60)
EPIDEMIOLOGY OF ADENOVIRUS RESPIRATORY INFECTIONS IN MILITARY RECRUIT POPULATIONS (1957) (60)
Clinical and Laboratory Studies of Live Cytomegalovirus Vaccine Ad-169 (1979) (60)
Clinical and Laboratory Studies of Combined Live Measles, Mumps, and Rubella Vaccines Using the RA 27/3 Rubella Virus (1980) (59)
Studies of acute respiratory illnesses caused by respiratory syncytial virus. 3. Clinical and laboratory findings. (1961) (58)
Studies in Chimpanzees of Live, Attenuated Hepatitis A Vaccine Candidates (1983) (57)
Persistence of Antibody in Human Subjects for 7 to 10 Years following Administration of Combined Live Attenuated Measles, Mumps, and Rubella Virus Vaccines (1980) (56)
Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies. (1971) (55)
Inducers of Interferon and Host Resistance VII. Antiviral Efficacy of Double-Stranded RNA of Natural Origin (1969) (54)
Critical appraisal of emulsified oil adjuvants applied to viral vaccines. (1966) (52)
Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing. (1968) (51)
Development and Chimpanzee Testing of a Vaccine against Human Hepatitis B (1976) (50)
Pneumococcal Vaccine: Dose, Revaccination, and Coadministration with Influenza Vaccine (1979) (49)
New Antigenic Variant in Far East Influenza Epidemic, 1957 (1957) (49)
Factors Influencing Tumor Induction in Hamsters by Vacuolating Virus, SV40.∗ (1963) (48)
Clinical and Laboratory Studies of KMcC Strain Live Attenuated Varicella Virus (1981) (47)
Six decades of vaccine development—a personal history (1998) (46)
Immunologic studies of measles. (1961) (46)
Stability on storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabilizer. (1980) (46)
Yeast recombinant hepatitis B vaccine (2005) (46)
Living attenuated measles-virus vaccine in early infancy. Studies of the role of passive antibody in immunization. (1961) (46)
Immunological Studies on the Psittacosis-lymphogranuloma Group of Viral Agents (1945) (45)
Induction of Interferon in Human Subjects by Poly I:C (1971) (44)
Seroepidemiologic Investigations of Human Hepatitis Caused by A, B, and a Possible Third Virus 1 (1976) (44)
Epidemiologic investigations with respiratory disease virus RI-67. (1955) (44)
Live, attenuated rubella-virus vaccine. (1968) (44)
Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDS. (1994) (43)
Double-stranded RNAs (poly I:C) in the prevention of viral infections. (1970) (43)
Persistence of Pneumococcal Antibodies in Human Subjects following Vaccination (1980) (43)
Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. (1975) (43)
DNA vaccines : a new era in vaccinology (1995) (42)
Use of living attenuated measles-virus vaccine in early infancy. (1960) (42)
Interferon induction and utilization (1968) (42)
Summary of worldwide clinical experience with H-B-Vax (B, MSD). (1983) (41)
Studies of acute respiratory illnesses caused by respiratory syncytial virus. 2. Epidemiology and assessment of importance. (1961) (41)
Inactivation of hepatitis B virus by three methods: Treatment with pepsin, urea, or formalin (1983) (41)
Efficacy of Live, Attenuated Measles-Virus Vaccine given with Human Immune Globulin. A Preliminary Report. (1961) (40)
Live rubella vaccines in adults and children. HPV-77 and Merck-Benoit strains. (1969) (39)
Live attenuated rubella virus vaccines. Experiences with duck embryo cell preparations. (1969) (39)
Polyvalent pneumococcal polysaccharide vaccines. (1978) (38)
Newer directions in vaccine development and utilization. (1985) (37)
Enzyme-linked immunosorbent assay for measurement of antibodies against pneumococcal polysaccharide antigens: comparison with radioimmunoassay (1979) (37)
Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution. (1968) (37)
Hyperpotentiation by Synthetic Double-Stranded RNA of Antibody Responses to Influenza Virus Vaccine in Adjuvant 65 (1969) (37)
Rubella Vaccination in Adult Females (1969) (37)
The Induction of Interferon (1971) (37)
Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines. (1978) (36)
Prevention of Acute Respiratory Illness in Recruits by Adenovirus∗ (RI-APC-ARD) Vaccine.† (1956) (36)
Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology (1999) (36)
The indirect complement fixation hemagglutination and conglutinating complement absorption tests for viruses of the psittacosis-lymphogranuloma venereum group. (1951) (35)
Comparison of Neutralization and Hemagglutination-Inhibition Techniques for Measuring Mumps Antibody (1967) (35)
Herpes simplex vaccines. (1976) (35)
Haemophilus influenzae Type b Polysaccharide-Protein Conjugate Vaccine (1987) (35)
Grouping and Occurrence of RI (Prototype RI-67) Viruses.∗ (1955) (34)
New Metabolizable Immunologic Adjuvant∗ for Human Use. I. Development and Animal Immune Response (1964) (34)
IMMUNOLOGIC, CHEMOTHERAPEUTIC AND INTERFERON APPROACHES TO CONTROL OF VIRAL DISEASE. (1965) (34)
Clinical and laboratory studies in patients with respiratory disease caused by adenoviruses (RI-APC-ARD agents). (1956) (33)
A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS. (1998) (33)
Epidemiology of RI(RI-67) group respiratory virus infections in recruit populations. (1955) (32)
The preparation and safety of hepatitis B vaccine. (1983) (32)
Biophysical Characterization of the RI (RI-67) Viruses.∗ (1955) (32)
Characterization of Chick Embryo Interferon Induced by a DNA Virus (1965) (32)
Clinical and laboratory findings in cases of respiratory illness caused by coryzaviruses. (1962) (31)
Antibody response in volunteers to Asian influenza vaccine. (1958) (31)
Appraisal of occurrence of adenovirus-caused respiratory illness in military populations. (1957) (31)
Live Respiratory Syncytial Virus Vaccine Administered Parenterally (1978) (30)
INTERFERON IN PROSPECT AND PERSPECTIVE. (1963) (30)
Live attenuated mumps virus vaccine. II. Early clinical studies. (1967) (29)
Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. (1998) (29)
Influence of age on clinical response to HPV-77 duck rubella vaccine. (1972) (29)
Clinical and Laboratory Studies of Live Attenuated RA 27/3 and HPV 77-DE Rubella Virus Vaccines (1980) (29)
Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man. (1956) (29)
Influence of Synthetic Double-Stranded Ribonucleic Acid, Poly I:G, on Friend Leukemia in Mice 1 (1969) (29)
The clinical application of adjuvant 65. (1972) (28)
Follow-Up Surveillance for Antibody in Human Subjects following Live Attenuated Measles, Mumps, and Rubella Virus Vaccines (1979) (28)
Comparative biology and pathogenesis of AIDS and hepatitis B viruses: related but different. (1994) (28)
Human hepatitis B vaccine from recombinant yeast. 1984. (1992) (28)
Influence of Polyamines on Induction of Interferon and Resistance to Viruses by Synthetic Polynucleotides (1969) (27)
Overview of the Needs and Realities for Developing New and Improved Vaccines in the 21st Century (2002) (27)
Impediments, imponderables and alternatives in the attempt to develop an effective vaccine against AIDS. (1992) (27)
Overview of vaccinology with special reference to papillomavirus vaccines. (2000) (27)
Past, present, and future of measles, mumps, and rubella virus vaccines. (1992) (27)
Influence of Size of Individual Homopolynucleotides on the Physical and Biological Properties of Complexed rIn:rCn (Poly I:C) (1970) (27)
Chemotherapy in bubonic lymphogranuloma venereum: a clinical and serological evaluation. (1957) (27)
Suitability of the Rufiventer Marmoset as a Host Animal for Human Hepatitis A Virus (1977) (26)
Feline leukemia virus envelope glycoprotein vaccine: preparation and evaluation of immunizing potency in guinea pig and cat. (1978) (26)
Influence of Synthetic (Poly I:C) and Viral Double-Stranded Ribonucleic Acids on Adenovirus 12 Oncogenesis in Hamsters∗ (1969) (26)
Hepatitis and hepatitis A vaccine: a glimpse of history. (1993) (26)
Differentiation of Virulent from Avirulent Measles Strains (1962) (26)
Epidemiologic Investigations of Rhinovirus Infections (1964) (26)
Further Investigations of Live Respiratory Syncytial Virus Vaccine Administered Parenterally (1979) (26)
Advances in control of viral infections by nonspecific measures and by vaccines, with special reference to live mumps and rubella virus vaccines (1966) (25)
Studies of Acute Respiratory Illnesses Caused by Respiratory Syncytial Virus. 1. Laboratory Findings in 109 Cases (1961) (25)
Laboratory and field investigations of bovine Myxovirus parainfluenza 3 virus and vaccine. I. Properties of the SF-4 (shipping fever) strain of virus. (1961) (25)
Relationship of Molecular Size of rIn:rCn (Poly I:C) to Induction of Interferon and Host Resistance (1970) (25)
Rubella virus vaccine (HPV-77-DE 5). Antigenic and protective efficacy in a community trial. (1969) (25)
OUTBREAK OF ACUTE RESPIRATORY ILLNESS CAUSED BY RI-67 AND INFLUENZA A VIRUSES, FORT LEONARD WOOD, 1952–1953, (1955) (24)
Influenza antibodies in the population of the USA; an epidemiological investigation. (1953) (24)
Development and utilization of complement-fixation and immune adherence tests for human hepatitis A virus and antibody. (1975) (24)
Isolation of Hepatitis A Virus in Vitro in Cell Culture Directly from Human Specimens (1981) (24)
Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine. (1971) (24)
Influence of Synthetic Double-Stranded Ribonucleic Acid (Poly I: C) on SV40 Viral Oncogenesis and Transplant Tumor in Hamsters 1 (1970) (23)
Studies of Oncogenicity of Adenovirus Type 7 Viruses in Hamsters.∗ (1965) (23)
Studies for safety of adjuvant 65. (1972) (23)
Enders' live measles-virus vaccine with human immune globulin. I. Clinical reactions. (1962) (23)
POLY I:C, AN INDUCER OF INTERFERON AND INTERFERENCE AGAINST VIRUS INFECTIONS (1972) (23)
Studies of live attenuated measles virus vaccine in man. II. Appraisal of efficacy. (1962) (22)
Toward control of viral infections of man. (1969) (22)
History, precedent, and progress in the development of mammalian cell culture systems for preparing vaccines: Safety considerations revisited (1990) (22)
Distribution and significance of Asian and other influenza antibodies in the human population. (1958) (22)
Additional Rhinovirus Serotypes (1964) (22)
Effective Treatment of Experimental Herpes Simplex Keratitis with New Derivative, 5-Methylamino-2′-Deoxyuridine (MADU) (1965) (21)
Production of purified hepatitis B surface antigen from Alexander hepatoma cells grown in artificial capillary units. (1983) (21)
Ender's live measles-virus vaccine with human immune globulin. II. Evaluation of efficacy. (1962) (21)
Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine. (1966) (21)
Antibody response in volunteers to adenovirus vaccine and correlation of antibody with immunity. (1958) (20)
Poly I:C/poly-L-lysine: potent inducer of interferons in primates. (1981) (20)
Double-Stranded Polynucleotides as Interferon Inducers (1970) (20)
Antigenic Pattern of Strains of Influenza A and B (1950) (20)
Line cell saga - an argument in favor of production of biologics in cancer cells. (1979) (19)
Jeryl Lynn Strain Live Attenuated Mumps Virus Vaccine: Influence of Age, Virus Dose, Lot, and γGlobulin Administration on Response (1968) (19)
Studies of live attenuated measles virus vaccine in man. I. Clinical aspects. (1962) (19)
Marek's disease vaccine: its implications in biology and medicine. (1972) (19)
Critical appraisal of emulsified oil adjuvants applied to viral vaccines. (1966) (18)
Studies on lymphogranuloma venereum complement-fixing antigens; enhancement by phenol or boiling. (1946) (18)
Influence of non-specific inhibitor on the diagnostic hemagglutination-inhibition test for influenza. (1953) (18)
Vaccine against Human Hepatitis B Virus Prepared from Antigen Derived from Human Hepatoma Cells in Culture (1984) (18)
Prevention of SV40 Virus Tumorigenesis by Irradiated, Disrupted and Iododeoxyuridine Treated Tumor Cell Antigens.∗ (1967) (18)
Respiratory viruses and respiratory virus vaccines. (1963) (18)
Vaccine Supply and Innovation (1987) (18)
Electron microscopy of type 4 adenovirus strain R1-67. (1957) (18)
Vaccines made from recombinant yeast cells. (1986) (17)
Experiences with Jeryl Lynn strain live attenuated mumps virus vaccine in a pediatric outpatient clinic. (1967) (17)
ADENOVIRUS (RI-APC-ARD) VACCINE FOR PREVENTION OF ACUTE RESPIRATORY ILLNESS: 2. FIELD EVALUATION (1957) (17)
Administration of Enders' live measles virus vaccine with human immune globulin. (1962) (17)
Laboratory studies on the 1950 outbreak of influenza. (1950) (17)
Efficacy of and indications for use of adenovirus vaccine. (1958) (16)
Laboratory and field investigations of bovine Myxovirus parainfluenza 3 virus and vaccine. III. Evaluation of an SF-4 (shipping fever) virus vaccine in cattle. (1961) (16)
New Metabolizable Immunologic Adjuvant∗ for Human Use. 2. Short-term Animal Toxicity Tests (1964) (16)
Multiple Molecular Species of Interferons of Mouse and of Rabbit Origin (1966) (16)
Scale‐up of Chick Cell Growth on Microcarriers in Fermenters for Vaccine Production (1983) (16)
Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine. (1995) (16)
Protective efficacy of duck embryo rubella vaccines. (1969) (16)
Search for Virus in Human Malignancies. 1. In vitro Studies.∗ (1962) (15)
RESPIRATORY SYNCYTIAL VIRUS. (1963) (15)
Physical, chemical and morphologic dimensions of human hepatitis A virus strain CR326 (38578). (1975) (15)
Vaccination of adults with live attenuated mumps virus vaccine. (1967) (15)
Combined live rubella-mumps virus vaccine. Findings in clinical-laboratory studies. (1971) (15)
DNA Vectors Precedents and Safety (1995) (15)
Rubella vaccination in adult females. (1969) (15)
Biophysical and biochemical properties of CR326 human hepatitis A virus. (1975) (15)
Recombinant vector vaccines in vaccinology. (1994) (15)
Respiratory Tract Diseases. (1961) (15)
Second field evaluation of bivalent Types 4 and 7 adenovirus vaccine. (1958) (15)
Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966. (1967) (14)
Clinical-laboratory experiences with combined dried live measles-smallpox vaccine. (1966) (14)
The dilemma of AIDS vaccine and therapy. Possible clues from comparative pathogenesis with measles. (1992) (14)
Whether and when an AIDS vaccine? (1995) (14)
THE PARAINFLUENZA VIRUSES OF MAN (1962) (14)
Enhancement in hamsters of virus oncogenesis attending vaccination procedures. (1965) (14)
Quality and safety of human hepatitis B vaccine. (1983) (14)
Adenovirus (RI-APC-ARD) vaccine for prevention of acute respiratory illness. I. Vaccine development. (1957) (14)
Respiratory virus vaccines. 8. Field evaluation of trivalent parainfluenza virus vaccine among preschool children in families, 1967-1968. (1969) (14)
Further Tests in Hamsters for Oncogenic Quality of Ordinary Viruses and Mycoplasma, with Correlative Review.∗ (1965) (14)
Combined live measles-mumps virus vaccine. (1973) (14)
System for Measuring and Designating Antigenic Components of Influenza Viruses with Analyses of Recently Isolated Strains (1951) (13)
Vaccination against acute respiratory illness of adenovirus (RI-APC-ARD) etiology. (1957) (13)
Failure of Thymopoietin, Ubiquitin and Synthetic Serum Thymic Factor to Restore Immunocompetence in T-Cell Deficient Mice (1978) (13)
Combined live measles-rubella virus vaccine. Findings in clinical laboratory studies. (1971) (13)
Studies on lymphogranuloma venereum complement-fixing antigens the solubility in ether of an active fraction. (1946) (13)
Cooperation between government and industry in combating a perceived emerging pandemic. The 1976 swine influenza vaccination program. (1996) (12)
Jeryl Lynn strain live mumps virus vaccine. Durable immunity for three years following vaccination. (1969) (12)
The business of science and the science of business in the quest for an AIDS vaccine. (1999) (12)
Immunologic Relations of the Psittacosis-Lymphogranuloma Group of Viral Agents.∗ (1944) (12)
Development of a purified poliomyelitis virus vaccine. (1961) (12)
Clinical and Laboratory Investigations of Monovalent and Combined Meningococcal Polysaccharide Vaccines, Groups A and C (1976) (12)
Immunologic Responses in Hamsters to Homologous Tumor Antigens Measured in vivo and in vitro ∗ (1967) (12)
Ten-Year Follow-Up Study for Safety of Adjuvant 65 Influenza Vaccine in Man (1973) (12)
Studies on Induction of Virus from Adenovirus and SV40 Hamster Tumors 1. Chemical and Physical Agents.∗ (1966) (12)
Viruses of special interest to the dermatologist; a review. (1950) (12)
Jeryl Lynn strain live attenuated mumps virus vaccine. Durability of immunity following administration. (1968) (11)
Respiratory virus vaccines. II. Mycoplasma pneumoniae (Eaton agent) vaccines. (1966) (11)
Antigenic relationships among adenoviruses with appraisal of reliability of complement-fixation test for typing isolates. (1958) (11)
New metabolizable immunologic adjuvant for human use. X. Long-term serologic and clinical follow-up. (1970) (11)
Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines. (1973) (11)
Persistent immunity following Enders live, attenuated measles-virus vaccine given with human immune globulin. (1962) (11)
Cells, vaccines and the pursuit of precedent. (1968) (11)
Studies on lymphogranuloma venereum complement-fixing antigens; fractionation with organic solvents of antigens of the psittacosis-lymphogranuloma venereum group. (1948) (11)
Respiratory virus vaccines. I. Respiratory syncytial and parainfluenza virus vaccines. (1966) (11)
Preparation and testing of duck embryo cell culture rubella vaccine. (1969) (11)
Double-Stranded RNA’s in Relation to Interferon Induction and Adjuvant Activity (1971) (11)
Host-Virus Relationships in Hamsters Inoculated with SV40 Virus During the Neonatal Period.∗ (1964) (11)
DURABLE IMMUNITY TWO YEARS AFTER ADMINISTRATION OF ENDERS'S LIVE MEASLES-VIRUS VACCINE WITH IMMUNE GLOBULIN. (1964) (10)
NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. 3. EFFICACY AND TOXICITY STUDIES IN MAN. (1964) (10)
Infectivity stability of live measles-virus vaccine. (1962) (10)
Characterization of CR326 human hepatitis A virus, a probable enterovirus. (1975) (10)
Immune adherence and complement-fixation tests for human hepatitis A. Diagnostic and epidemiologic investigations. (1975) (10)
Attempt at Immunization by Oral Feeding of Live Rhinoviruses in Enteric-Coated Capsules (1966) (10)
A Field Trial of Combined Measles- Mumps-Rubella Vaccine (1973) (10)
Serologic responses to split and whole swine influenza virus vaccines in light of the next influenza pandemic. (1977) (10)
Adenovirus vaccine; development, field evaluation, and appraisal of the need for vaccination in military and civilian populations. (1958) (9)
Prevention of Viral and Transplant Tumors in Hamsters Employing Killed and Fragmented Homologous Tumor Cell Vaccines∗ (1968) (9)
The Effect of Altering the Size of Poly C on the Toxicity and Antigenicity of Poly I:C (1972) (9)
The roles of early alert and of adjuvant in the control of Hong Kong influenza by vaccines. (1969) (9)
Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. (2000) (9)
Optimization techniques: Studies in cell culture (1983) (9)
Attempts to Interrupt Virus Tumorigenesis by Immunization Using Homologous “Bjorklund-Type” Antigen.∗ (1963) (9)
Comparison of the antigenic patterns of influenza A virus strains determined by in ovo neutralization and hemagglutination-inhibition. (1952) (9)
Measurement of immunity following live mumps (5 years), measles (3 years), and rubella (2 and one-half years) virus vaccines. (1972) (9)
A FORWARD LOOK AT VIRAL VACCINES: WITH SPECIAL REFERENCE TO A NEW IMMUNOLOGIC ADJUVANT. (1964) (9)
Personal reflections on twentieth century vaccinology. (2003) (8)
Complement-Fixation Reaction of Human Neoplastic Tissue with Sera From Hamsters Bearing Virus-Induced Tumors.∗ (1967) (8)
Antigenicity of Double-Stranded Ribonucleic Acids Including Poly I:C (1972) (8)
New metabolizable immunologic adjuvant for human use. 5. Evaluation of highly purified influenza-virus vaccine in adjuvant 65. (1967) (8)
Immunogenic response to killed measles-virus vaccine. Studies in animals and evaluation of vaccine efficacy in an epidemic. (1962) (8)
Persistence of immunity four years following Jeryl Lynn strain live mumps virus vaccine. (1970) (8)
Infectious hepatitis (hepatitis A) research in nonhuman primates. (1977) (8)
Prevention of SV40 Virus Tumorigenesis in Newborn Hamsters by Maternal Immunization.∗ † (1967) (7)
Hepatitis B and AIDS and the promise for their control by vaccines. (1988) (7)
Infection and Immunization of Cats with the Kawakami-Theilen Strain of Feline Leukemia Virus 1 (1979) (7)
Influenza B in the Spring of 1965 (1966) (7)
Immunologic Prevention of Human Hepatitis (1984) (7)
Whither immunization against viral infections? (1984) (7)
Development of Immunity Against Hepatitis A Virus by Subclinical Infection 1 (1976) (7)
Acute respiratory illness in volunteers following intramuscular administration of live adenovirus. (1957) (7)
Improving the heat stability of vaccines: problems, needs, and approaches. (1989) (7)
A PROTECTIVE ANTISERUM AGAINST MOUSE PNEUMONITIS VIRUS. (1943) (7)
Acute respiratory illness caused by adenoviruses; a military problem. (1956) (6)
POLIOVIRUS VACCINES IN MINERAL OIL ADJUVANT. II. CLINICAL REACTION AND ANTIBODY RESPONSE. (1963) (6)
In vivo and in vitro studies of serological specificity among viruses of the psittacosis-lymphogranuloma venereum group. (1952) (6)
Measles, mumps and rubella virus vaccines prepared from virus produced by unit process. (1975) (6)
Cellular Control of Interferon Production and Release After Treatment with Poly I:C Inducer (1972) (6)
The Development of Live Attenuated Mumps Virus Vaccine in Historic Perspective and Its Role in the Evolution of Combined Measles–Mumps–Rubella (2011) (6)
Studies on Induction of Virus from Adenovirus and SV40 Hamster Tumors 2. “Helper” Viruses.∗ (1966) (6)
Antibody Response in Man to Hong Kong Influenza Following 1967 Formula Influenza Vaccine in Adjuvant 65 (1969) (6)
Virus vaccines (1985) (6)
Progress toward a live attenuated human hepatitis A virus vaccine. (1983) (6)
CLINICAL-EPIDEMIOLOGIC FINDINGS IN CORYZAVIRUS INFECTIONS. (1963) (6)
Vaccines against hepatitis A and B (1993) (6)
Laboratory and field investigations of bovine Myxovirus parainfluenza 3 virus and vaccine. II. Development and appraisal of potency of SF-4 (shipping fever) virus vaccine. (1961) (6)
Human cancer virus vaccines and the pursuit of the practical (1974) (6)
Historical and contemporary perspectives in vaccine developments: from the vantage of cancer. (1992) (6)
A FORWARD LOOK AT VIRAL VACCINES: WITH SPECIAL REFERENCE TO A NEW IMMUNOLOGIC ADJUVANT. (1964) (6)
Do family planning facilities meet the needs of the sexually active teenagers (1988) (5)
Coloscopy: endoscopic examination of the colon. (1956) (5)
The Promise and the Reality of Viral Vaccines against Cancer (1993) (5)
Studies on lymphogranuloma venereum complement-fixing antigens; fractionation with organic solvents of antigens of the psittacosis lymphogranuloma venereum group. (1947) (5)
Group-specificity of psittacosis-lymphogranuloma venereum group skin test antigens in lymphogranuloma venereum patients. (1958) (5)
Effect of Westphal Lipid A on Viral Activities in Mice and Hamsters (1962) (5)
Present knowledge of the rhinovirus group of viruses. (1967) (5)
Tests in rufiventer and other marmosets of susceptibility to human hepatitis A virus. (1978) (5)
A guinea pig potency test for adenovirus vaccine. (1960) (5)
POLIOVIRUS VACCINES IN MINERAL OIL ADJUVANT. I. ANIMAL TOXICITY AND SEROLOGIC RESPONSE DATA. (1963) (5)
Tests for Oncogenicity of Viruses Under Conditions of Altered Host and Virus 1 (1971) (5)
Search for Virus in Human Malignancies. 2. In vivo Studies.∗ (1962) (5)
New metabolizable immunologic adjuvant for human use. IX. Large-scale trials with multiple lots in different regimens. (1969) (5)
SOME PRECLINICAL STUDIES IN ANIMAL MODELS WITH DOUBLE‐STRANDED RNA'S (1970) (5)
The control of viral diseases, with special reference to mumps, rubella, and interferon (1968) (5)
PROSPECTS FOR THE ROLE OF VIRUSES IN HUMAN MALIGNANCY. (1964) (5)
Present knowledge of the rhinovirus group of viruses. (1967) (5)
Vaccines for the decade of the 1980s and beyond. (1982) (4)
Immunologic responses in hamsters to homologous tumor antigens measured in vivo and in vitro (1967) (4)
Vaccinology in practical perspective. (1986) (4)
Development of anal ducts and glands with reference to the pathogenesis of anorectal disease. (1949) (4)
New Metabolizable Immunologic Adjuvant for Human Use. 4. Development of Highly Purified Influenza Virus Vaccine in Adjuvant 65 (1966) (4)
THE ECHO 28-RHINOVIRUS-CORYZAVIRUS (ERC) GROUP OF VIRUSES. (1963) (4)
Respiratory virus vaccines. 3. Pentavalent respiratory syncytial-parainfluenza-mycoplasma pneumoniae vaccine. (1966) (4)
Rhinovirus Infection in Nursery and Kindergarten Children. New Rhinovirus Serotype 54 (1967) (4)
International biological standardization in historic and contemporary perspective. (1999) (4)
CHAPTER 19 – Prospects for Vaccines against Cancer (1974) (4)
New developments with new vaccines. (1980) (4)
Status report on adenoviruses and Asian influenza. (1958) (4)
Combined Measles, Mumps, and Rubella Vaccines (1999) (4)
Laryngocele: an unusual tumor of the neck; case report. (1954) (4)
Stabilized measles vaccine in a novel single-dose delivery system: a practical reality for worldwide elimination of measles. (1983) (4)
Variations in immunogenicity of disrupted cells prepared from an adenovirus-7 hamster tumor cell line. (1971) (4)
Clinical laboratory experiences with a more attenuated Enders' measles virus vaccine (Moraten) combined with smallpox vaccine. (1969) (3)
Lack of identity of polyoma virus and pneumonia virus of mice (PVM). (1960) (3)
Historical and contemporary perspectives in vaccine developments: from the vantage of cancer. (1992) (3)
The Frustrating Journey toward an AIDS Vaccine (2000) (3)
Porcine stress deaths (1992) (3)
Microelectrode probes for biomedical applications. (1990) (3)
A safe high-speed blendor for processing infectious materials. (1958) (3)
RESPIRATORY SYNCYTIAL VIRUS. (1963) (3)
Demonstration of Double-Stranded Ribonucleic Acid in Concentrates of RNA Viruses (1972) (3)
Alopecia in calves associated with milk substitute feeding (1983) (3)
Cells, vaccines, and the pursuit of precedent. (1968) (3)
Clinical Laboratory Evaluation of Rubella Virus Vaccine Given to Postpartum Women Without Pregnancy Preventive (1973) (3)
Use of living attenuated measles-virus vaccine in early infancy. (1960) (3)
Search for Virus in Human Malignancies. 4. Tests of Human Neoplastic Tissues in Sex-Segregated Mice.∗ (1966) (3)
Occurrence and significance of adenovirus antibody in sera of recruit and cadre military personnel. (1958) (3)
Overview: Past and future of immunologic intervention in the pathogenesis, prophylaxis and therapeusis of hepatitis B (2002) (3)
Respiratory viruses and respiratory virus vaccines. (1963) (3)
Recombinant yeast hepatitis B vaccine. (1986) (3)
In Vitro Safety Assessment of Double-Stranded Polynucleotides Poly I:C and Mu-9 (1971) (3)
Respiratory virus vaccines. VI. Serologic responses to heptavalent vaccine among young children in families. (1967) (3)
Overview of Vaccinology in Historic and Future Perspective (2003) (3)
A novel single-dose delivery system for vaccines. (1982) (3)
On Use of Urea- and Phenol-Treated Skin Test Antigens for Diagnosis of Lymphogranuloma venereum. (1947) (3)
Preparation of dried antigen and antiserum for the agglutination-inhibition test for virus influenza. (1951) (3)
Human cancer virus vaccines (1974) (2)
Immunologic response in hamsters to homologous tumor antigens measured in vivo and in vitro. (1967) (2)
Field evaluation of combined more attenuated live measles (Moraten)-smallpox vaccine in Honduras and Costa Rica. (1971) (2)
Overview of viruses, cancer, and vaccines in concept and in reality. (1998) (2)
High-resolution flow-zonal centrifuge system. (1979) (2)
The Quality of Measles Virus Vaccine (1965) (2)
Respiratory virus vaccines. IV. Heptavalent respiratory syncytial-parainfluenza-mycoplasma-influenza vaccine in institutionalized persons. (1966) (2)
The role of industry in the development of new biologicals. (1977) (2)
Perspectives for testing safety of live measles vaccine. (1962) (2)
Present status of recombinant hepatitis B vaccine. (1988) (2)
Jeryl Lynn strain live mumps virus vaccine. (1969) (2)
An evaluation of the surgical treatment of carcinoma of the stomach. (1956) (2)
A pattern of antigen variation. (1952) (2)
Cells, vaccines and the pursuit of precedent. (1968) (2)
Conclusions: in pursuit of an AIDS virus vaccine. (1989) (2)
Hepatitis viruses and vaccines (1978) (2)
The science of vaccines in present and future perspective (1986) (2)
ECHO virus, type 25, in respiratory illness. Case report. (1963) (2)
Preparation of dried antigen and antiserum for the agglutination-inhibition test for virus influenza. (1951) (2)
Strategies for the achievement of prophylactic vaccination against HIV. (1996) (2)
Three Decades of Hepatitis Vaccinology in Historic Perspective. A Paradigm of Successful Pursuits (2011) (2)
Use of poly I-poly C in the prophylaxis and treatment of acute viral infections. (1969) (1)
Viral Hepatitis and Liver Disease: Editor, A.J. Zuckerman, Alan R. Liss, Inc., New York, 1988, 1160 pp., $350.00, ISBN 0-8451-4247-X (1989) (1)
A safe high-speed blendor for processing infectious materials. (1958) (1)
The Evaluation of Vaccines (1985) (1)
Detection of poliovirus I in monkey kidney cultures inoculated with overwhelming dose of adenovirus 4. (1958) (1)
New Metabolizable Immunologic Adjuvant∗ for Human Use 8. Chronic Toxicity and Teratogenic Tests (1968) (1)
Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells (1980) (1)
Vaccine, chemotherapy, and host resistance approaches to control of viral respiratory disease. (1966) (1)
Concerns for the use of continuous cell lines and certain promoters for producing vaccine antigens by recombinant technology. (1987) (1)
PURSUIT OF PRACTICABLE IMMUNOGENS FOR HUMAN NEOPLASIA (1968) (1)
Status report on adenoviruses and Asian influenza. (1958) (1)
Vaccines, human experimentation, and ethics in evolutionary perspective. (1998) (1)
Pneumonia and meningoencephalitis in a female adolescent. Case report. (1984) (1)
Automated cytopathic effect (CPE) assays. (1983) (1)
Search for Virus in Human Malignancies. 3. Sex Segregation and Neoplasia in ICR/Ha Mice.∗ (1963) (1)
Cryosurgical Treatment of Primary SV40 Viral and Adenovirus 7 Transplant Tumors in Hamsters∗ (1968) (1)
New developments with new vaccines. (1980) (1)
How does a viral infection trigger an autoimmune disease (1995) (1)
Vaccination against mumps. (1968) (1)
Viral Enhancement and Interference Induced in Cell Culture by Hepatitis A Virus: Application to Quantitative Assays for Hepatitis A Virus (1984) (1)
Safety Assessment of Poly I: C in NZB/NZW Mice (1975) (1)
Perspectives in the control of viral diseases including cancer. (1972) (1)
Vaccines for the decade of the 1980s and beyond. (1982) (1)
What is the most important achievement in viral immunology in the last five years (1995) (1)
The 1975 I.R.I. Achievement Award Lecture: Managing Research in the Health Sciences (1976) (1)
PROSPECTS FOR THE ROLE OF VIRUSES IN HUMAN MALIGNANCY. (1964) (1)
Perspectives in Disease Prevention by Vaccines (1987) (1)
Toward control of viral infections of man. Such control is viewed from the standpoint of the possible, the probable, and the practical. (1969) (1)
Preparation of Measles Antiserum in Horses (1962) (1)
Problems and potentials for human viral cancer vaccines. (1972) (1)
Comparative Studies of SV40 and Adenovirus Oncogenesis in Random Bred and Inbred Hamsters 1 (1971) (1)
DISCUSSION (1971) (0)
Immunologic Attack on Neoplasia (1966) (0)
Mechanical apparatus for washing tissue cultures in tubes. (1955) (0)
What are the major goals of research in viral immunology (1995) (0)
Toward Prophylaxis of Prenatal Infection by Viruses (1969) (0)
Preparation and Research on Meningococcal Vaccines (1972) (0)
A tribute to Professor Friedrich W. Deinhardt, scientist and statesman, 1926–1992 (1993) (0)
Mumps vaccination. (1970) (0)
Preface (1995) (0)
New Hepatitis A and B Vaccines: Summary of a Specialty Session (1994) (0)
Fritz will be remembered, for he was a servant to mankind and the world is a better place, because he was here. On this last fallen leaf, we inscribe our final tribute to Fritz, 'Farewell, good Friend; well done!' (1992) (0)
Vaccination against mumps. (1968) (0)
A tribute to Dr. Friedrich W. Deinhardt M.D. 1926-1992. (1993) (0)
Prophylaxe intrauteriner Virusinfektion (1970) (0)
Is immunization with naked DNA the most important factor in the development of vaccines (1995) (0)
Present status of recombinant hepatitis B vaccine. (1988) (0)
Human papillomavirus vaccination workshop, Helsinki 10.01.2000: Structured discussion (2000) (0)
Visualization of bacterial polysaccharides by scanning transmission electron microscopy. (1983) (0)
Failure of Shier's Chemical Vaccine to Protect BALB/c Mice Against Transplant and Chemically Induced Tumors 1 (1974) (0)
Regularly scheduled versus as-needed use of inhaled beta agonists in the treatment of asthma. (1992) (0)
On the oncogenicity of ordinary viruses (2005) (0)
The polysaccharide / protein conjugate, process for its preparation and its use in a vaccine (1984) (0)
Subject Index Vol. 45, 2002 (2002) (0)
A process for increasing the activity of a vaccine. (1969) (0)
Conclusions: in pursuit of an AIDS virus vaccine. (1989) (0)
An automatic pipette for preparing serial dilutions. (1952) (0)
A pattern of antigen variation. (1952) (0)
A device for storage and dispensing of vaccines and method of loading of the device (1976) (0)
Invited Discussions Double-Stranded Polynucleotides as Interferon Inducers (0)
[Research of infectious hepatitis (hepatitis A) in non-human primates]. (1976) (0)
Respiratory Tract Diseases (1961) (0)
Vaccinology in practical perspective. (1986) (0)
Two-team abdomino-perineal operation for carcinoma of rectum and rectosigmoid. (1947) (0)
Letter from Maurice R. Hilleman to Paul Berg (1973) (0)
New immunologic adjuvant for human use. II. Short-term animal toxicity tests (1964) (0)
DISCUSSION (1967) (0)
Viral vaccines in historical perspective. (1995) (0)
Contents Vol. 45, 2002 (2002) (0)
The Newer Live Virus Vaccines (2009) (0)
Hepatitis B can teach about how to approach the development of a vaccine against AIDS (1996) (0)
Part II. Mechanism of DNA Uptake and Antigen Presentation: Fate and Function of Foreign Nucleic Acids Use of Plasmid DNA for Direct Gene Transfer and Immunization. (1995) (0)
Use of poly I-poly C in the prophylaxis and treatment of acute viral infections. (1969) (0)
Discussion. Mycoplasma from human respiratory and urogenital tract. (1967) (0)
Long-Term Follow-up for Immunity After Monovalent or Combined Live Measles, Mumps, and Rubella Virus Vaccines (1975) (0)
IXth International Congress of Infectious and Parasitic Diseases Munich, July 20–26, 1986 (2005) (0)
A review of DNA vaccines (2007) (0)
A simple tissue washer. (1951) (0)
Prof. Dr. F. Deinhardt — 60 years (2005) (0)
The control of viral respiratory illnesses of man. (1962) (0)
Studies of immunization with three types of combined viral vaccines (1971) (0)
The control of viral respiratory illnesses of man. (1962) (0)
Toward prophylaxis of prenatal infection by viruses. (1969) (0)
Lactose absorption, milkconsumption, andfasting blood glucose concentrations inwomenwithidiopathic osteoporosis (1986) (0)
Discussion. Mycoplasma from human respiratory and urogenital tract. (1967) (0)
ON THE ONCOGENICITY OF ORDINARY VIRUSES. (1965) (0)
A simple tissue washer. (1951) (0)
Vaccine, chemotherapy, and host resistance approaches to control of viral respiratory disease. (1966) (0)
The role of industry in the development of new biologicals. (1977) (0)
[Advances and new approach in the control of virus diseases in man]. (1970) (0)
The enhancement and properties of the complement-fixing antigens of lymphogranuloma venereum. (1946) (0)

This paper list is powered by the following services:

Other Resources About Maurice Hilleman

en.wikipedia.org

What Schools Are Affiliated With Maurice Hilleman?

Maurice Hilleman is affiliated with the following schools:

Maurice Hilleman's AcademicInfluence.com Rankings

Image Attributions

Image Source for Maurice Hilleman